Skip to content

Evaluate blood pressure lowering drugs in hypertensive pregnant patients before caesarean delivery

Evaluation of intravenously used anti-hypertensive drugs for preoperative blood pressure control in patients with hypertensive disorders of pregnancy undergoing caesarean delivery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/05/013709
Enrollment
150
Registered
2018-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Pregnant patients with hypertension

Interventions

Intervention1: hydralazine: 5 mg intravenous over 2 minutes Control Intervention1: Labetalol: 20 mg intravenous over 2 minutes

Sponsors

Department of Anaesthesiolgy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. patients with systolic blood pressure more than or equal to 160 mmHg and/or diastolic blood pressure more than or equal to 110 mmHg 2. single or multiple pregnancy 3. gestational age >24 weeks

Exclusion criteria

Exclusion criteria: 1. patients who did not consent 2. any known allergy to drugs used (hydralazine and labetalol)

Design outcomes

Primary

MeasureTime frame
time taken to reach adequate control of blood pressure (systolic blood pressure 140-150 mmHg and/or diastolic blood pressure 90-100 mmHg)Timepoint: every 2 minutes till control of blood pressure achieved

Secondary

MeasureTime frame
1. efficacy of drugs used (number of doses required for adequate control of blood pressure) 2. number of patients who achieved adequate control of blood pressure 3. incidence of persistent hypertension 4. adverse effects of drugs used 5. maternal outcomes 6. fetal outcomesTimepoint: every 10 minutes till adequate control of blood pressure

Countries

India

Contacts

Public ContactRanju Singh

Lady Hardinge Medical College

ranjusingh1503@yahoo.com9811151285

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026